Glenmark Pharmaceuticals Ltd

BSE: 532296

total announcements

532296.BO · 15 min delayed

BSECompany UpdateResults1d ago

Intimation of Earnings Call

Glenmark Pharmaceuticals Ltd has announced an earnings call for its unaudited financial results for the quarter ended June 30, 2026, scheduled to be held on August 03, 2026. The call will cover the company's Q1 FY 2027 results.

Glenmark receives U.S. FDA approval to expand the use of RYALTRIS Nasal Spray for Children aged 6 to less than 12 years

Glenmark Pharmaceuticals Ltd has received U.S. FDA approval to expand the use of RYALTRIS Nasal Spray for children aged 6 to less than 12 years for the treatment of symptoms of Seasonal Allergic Rhinitis.